State Street’s Contineum Therapeutics CTNM Stock Holding History

State Street’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.32M	Buy	101,278 +16,850	+20%	+$226K	﹤0.01%	3421
2025 Q4	$965K	Buy	84,428 +22,000	+35%	+$251K	﹤0.01%	3532
2025 Q3	$734K	Buy	62,428 +33,528	+116%	+$270K	﹤0.01%	3579
2025 Q2	$115K	Sell	28,900 -97,964	-77%	-$426K	﹤0.01%	3951
2025 Q1	$886K	Buy	126,864 +2,120	+2%	+$19.3K	﹤0.01%	3459
2024 Q4	$1.83M	Buy	124,744 +11,178	+10%	+$177K	﹤0.01%	3347
2024 Q3	$2.17M	Buy	113,566 +21,760	+24%	+$417K	﹤0.01%	3300
2024 Q2	$1.62M	Buy	+91,806	New	+$1.48M	﹤0.01%	3385

Other funds holding CTNM

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street's CTNM Position: Q1 2026 in Review

State Street increased its Contineum Therapeutics (CTNM) stake by 20% in Q1 2026, buying an estimated $226K and bringing the position to 101,278 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #3421.

State Street first reported a position in CTNM in Q2 2024 and has held it in 8 quarters since. The position peaked at $2.17M in Q3 2024. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

State Street held 101,278 shares of Contineum Therapeutics worth $1.32M as of Q1 2026.
State Street bought 16,850 Contineum Therapeutics shares in Q1 2026, an estimated $226K.
Contineum Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3421 holding.
State Street first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 8 quarters since.
State Street's Contineum Therapeutics position peaked at $2.17M in Q3 2024.
90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.